Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?
Purpose PTEN and KLLN are two tumor suppressor genes located in 10q23, share a bidirectional promoter and have roles in carcinogenesis. Formerly, the role of PTEN mutations and KLLN epimutations were identified in incidence of thyroid lesions in individuals with Cowden syndrome, a rare autosomal dom...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2017-09, Vol.57 (3), p.428-435 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 435 |
|---|---|
| container_issue | 3 |
| container_start_page | 428 |
| container_title | Endocrine |
| container_volume | 57 |
| creator | Razavi, S. Adeleh Modarressi, Mohammad Hossein Yaghmaei, Parichehr Tavangar, S. Mohammad Hedayati, Mehdi |
| description | Purpose
PTEN
and
KLLN
are two tumor suppressor genes located in 10q23, share a bidirectional promoter and have roles in carcinogenesis. Formerly, the role of
PTEN
mutations and
KLLN
epimutations were identified in incidence of thyroid lesions in individuals with Cowden syndrome, a rare autosomal dominant inherited disorder. This study is the first of its type to assess PTEN and KLLN circulating levels in patients with sporadic papillary thyroid carcinoma (PTC) and compare to patients with multinodular goiter (MNG) and healthy individuals.
Methods
Plasma levels of PTEN and KLLN were determined by enzyme-linked immunosorbent assay in three groups consisted of PTC (
n
= 33), MNG (
n
= 26) and healthy persons (
n
= 30). The association of demographic/pathological characteristics with the levels of PTEN and KLLN were evaluated.
Results
A significant lower plasma levels of PTEN and KLLN were observed in PTC patients compared with those of healthy persons (PTEN, 9.43 ± 3.20 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.81 ± 0.83 vs. 2.57 ± 1.09 ng/ml,
P
= 0.005), while no statistical difference was found between PTC and MNG groups. Patients with MNG lesion had significantly lower levels of PTEN/KLLN (PTEN, 9.62 ± 2.97 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.34 ± 0.86 vs. 2.57 ± 1.09 ng/ml,
P
= 0.000) compared to the healthy controls. The demographic/pathological characteristics did not demonstrate an association with the levels of PTEN and KLLN.
Conclusions
The study suggests that the lowered levels of PTEN and KLLN are associated with both sporadic PTC and MNG tumorigenesis, but they cannot be considered as circulating biomarkers for differential diagnosis between malignancy and benignity in indeterminate thyroid nodules. |
| doi_str_mv | 10.1007/s12020-017-1368-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1933276656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1933276656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-f3b50b4867e9e767c57f709138af1a1ff23c5f1b22ed37ba6e8d0fcf8bafaefd3</originalsourceid><addsrcrecordid>eNp1kE1PGzEQhq2KqnyUH8ClssR5YWzH600vqIroh4gChyBxs7z2OJgudmpvKqW_HqNQxIXTjGbe953RQ8gJgzMGoM4L48ChAaYaJtqumXwgB0zKaZ0A7NVeSNkAdHf75LCUBwDOeas-kX3eKSnZBA7Iv1nIdjOYMcQVHfAvDoUmT2-WlwtqoqNX8_mChkjXZh2GweQtHe-3OQVHrck2xPRovtY21jFuaY_UpliCw4yOmkJjqonUBbOKqYzB0j5UR_6NuVx8Jh-9GQoev9Qjcvv9cjn72cyvf_yafZs3Vig-Nl70EvpJ1yqcomqVlcormDLRGc8M854LKz3rOUcnVG9a7Bx467veeIPeiSNyustd5_Rng2XUD2mTYz2p2VQIrtpWtlXFdiqbUykZvV7nUF_dagb6mbbe0daVtn6mrSfV8-UledM_ont1_MdbBXwnKHUVV5jfnH439QkjWova</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1933276656</pqid></control><display><type>article</type><title>Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Razavi, S. Adeleh ; Modarressi, Mohammad Hossein ; Yaghmaei, Parichehr ; Tavangar, S. Mohammad ; Hedayati, Mehdi</creator><creatorcontrib>Razavi, S. Adeleh ; Modarressi, Mohammad Hossein ; Yaghmaei, Parichehr ; Tavangar, S. Mohammad ; Hedayati, Mehdi</creatorcontrib><description>Purpose
PTEN
and
KLLN
are two tumor suppressor genes located in 10q23, share a bidirectional promoter and have roles in carcinogenesis. Formerly, the role of
PTEN
mutations and
KLLN
epimutations were identified in incidence of thyroid lesions in individuals with Cowden syndrome, a rare autosomal dominant inherited disorder. This study is the first of its type to assess PTEN and KLLN circulating levels in patients with sporadic papillary thyroid carcinoma (PTC) and compare to patients with multinodular goiter (MNG) and healthy individuals.
Methods
Plasma levels of PTEN and KLLN were determined by enzyme-linked immunosorbent assay in three groups consisted of PTC (
n
= 33), MNG (
n
= 26) and healthy persons (
n
= 30). The association of demographic/pathological characteristics with the levels of PTEN and KLLN were evaluated.
Results
A significant lower plasma levels of PTEN and KLLN were observed in PTC patients compared with those of healthy persons (PTEN, 9.43 ± 3.20 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.81 ± 0.83 vs. 2.57 ± 1.09 ng/ml,
P
= 0.005), while no statistical difference was found between PTC and MNG groups. Patients with MNG lesion had significantly lower levels of PTEN/KLLN (PTEN, 9.62 ± 2.97 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.34 ± 0.86 vs. 2.57 ± 1.09 ng/ml,
P
= 0.000) compared to the healthy controls. The demographic/pathological characteristics did not demonstrate an association with the levels of PTEN and KLLN.
Conclusions
The study suggests that the lowered levels of PTEN and KLLN are associated with both sporadic PTC and MNG tumorigenesis, but they cannot be considered as circulating biomarkers for differential diagnosis between malignancy and benignity in indeterminate thyroid nodules.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-017-1368-4</identifier><identifier>PMID: 28755140</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Biomarkers ; Biomarkers, Tumor - blood ; Carcinogenesis ; Carcinoma, Papillary - blood ; Carcinoma, Papillary - diagnosis ; Carcinoma, Papillary - pathology ; Case-Control Studies ; Chromosome 10 ; Cowden syndrome ; Diabetes ; Diagnosis, Differential ; Differential diagnosis ; Down-Regulation ; Endocrinology ; Enzyme-Linked Immunosorbent Assay ; Female ; Goiter ; Goiter, Nodular - blood ; Goiter, Nodular - diagnosis ; Hereditary diseases ; Humanities and Social Sciences ; Humans ; Internal Medicine ; Iran ; Male ; Malignancy ; Medicine ; Medicine & Public Health ; Middle Aged ; multidisciplinary ; Neoplasm Staging ; Nodules ; Normal Distribution ; Original Article ; Papillary thyroid carcinoma ; Plasma levels ; PTEN Phosphohydrolase - blood ; PTEN protein ; Science ; Statistics, Nonparametric ; Thyroid ; Thyroid cancer ; Thyroid Cancer, Papillary ; Thyroid Gland - pathology ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - pathology ; Tumor Burden ; Tumor suppressor genes ; Tumor Suppressor Proteins - blood ; Tumorigenesis</subject><ispartof>Endocrine, 2017-09, Vol.57 (3), p.428-435</ispartof><rights>Springer Science+Business Media, LLC 2017</rights><rights>Copyright Springer Science & Business Media 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-f3b50b4867e9e767c57f709138af1a1ff23c5f1b22ed37ba6e8d0fcf8bafaefd3</citedby><cites>FETCH-LOGICAL-c372t-f3b50b4867e9e767c57f709138af1a1ff23c5f1b22ed37ba6e8d0fcf8bafaefd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-017-1368-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-017-1368-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28755140$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Razavi, S. Adeleh</creatorcontrib><creatorcontrib>Modarressi, Mohammad Hossein</creatorcontrib><creatorcontrib>Yaghmaei, Parichehr</creatorcontrib><creatorcontrib>Tavangar, S. Mohammad</creatorcontrib><creatorcontrib>Hedayati, Mehdi</creatorcontrib><title>Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
PTEN
and
KLLN
are two tumor suppressor genes located in 10q23, share a bidirectional promoter and have roles in carcinogenesis. Formerly, the role of
PTEN
mutations and
KLLN
epimutations were identified in incidence of thyroid lesions in individuals with Cowden syndrome, a rare autosomal dominant inherited disorder. This study is the first of its type to assess PTEN and KLLN circulating levels in patients with sporadic papillary thyroid carcinoma (PTC) and compare to patients with multinodular goiter (MNG) and healthy individuals.
Methods
Plasma levels of PTEN and KLLN were determined by enzyme-linked immunosorbent assay in three groups consisted of PTC (
n
= 33), MNG (
n
= 26) and healthy persons (
n
= 30). The association of demographic/pathological characteristics with the levels of PTEN and KLLN were evaluated.
Results
A significant lower plasma levels of PTEN and KLLN were observed in PTC patients compared with those of healthy persons (PTEN, 9.43 ± 3.20 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.81 ± 0.83 vs. 2.57 ± 1.09 ng/ml,
P
= 0.005), while no statistical difference was found between PTC and MNG groups. Patients with MNG lesion had significantly lower levels of PTEN/KLLN (PTEN, 9.62 ± 2.97 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.34 ± 0.86 vs. 2.57 ± 1.09 ng/ml,
P
= 0.000) compared to the healthy controls. The demographic/pathological characteristics did not demonstrate an association with the levels of PTEN and KLLN.
Conclusions
The study suggests that the lowered levels of PTEN and KLLN are associated with both sporadic PTC and MNG tumorigenesis, but they cannot be considered as circulating biomarkers for differential diagnosis between malignancy and benignity in indeterminate thyroid nodules.</description><subject>Adult</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinogenesis</subject><subject>Carcinoma, Papillary - blood</subject><subject>Carcinoma, Papillary - diagnosis</subject><subject>Carcinoma, Papillary - pathology</subject><subject>Case-Control Studies</subject><subject>Chromosome 10</subject><subject>Cowden syndrome</subject><subject>Diabetes</subject><subject>Diagnosis, Differential</subject><subject>Differential diagnosis</subject><subject>Down-Regulation</subject><subject>Endocrinology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Goiter</subject><subject>Goiter, Nodular - blood</subject><subject>Goiter, Nodular - diagnosis</subject><subject>Hereditary diseases</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Iran</subject><subject>Male</subject><subject>Malignancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Neoplasm Staging</subject><subject>Nodules</subject><subject>Normal Distribution</subject><subject>Original Article</subject><subject>Papillary thyroid carcinoma</subject><subject>Plasma levels</subject><subject>PTEN Phosphohydrolase - blood</subject><subject>PTEN protein</subject><subject>Science</subject><subject>Statistics, Nonparametric</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Thyroid Cancer, Papillary</subject><subject>Thyroid Gland - pathology</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - diagnosis</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Tumor Burden</subject><subject>Tumor suppressor genes</subject><subject>Tumor Suppressor Proteins - blood</subject><subject>Tumorigenesis</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PGzEQhq2KqnyUH8ClssR5YWzH600vqIroh4gChyBxs7z2OJgudmpvKqW_HqNQxIXTjGbe953RQ8gJgzMGoM4L48ChAaYaJtqumXwgB0zKaZ0A7NVeSNkAdHf75LCUBwDOeas-kX3eKSnZBA7Iv1nIdjOYMcQVHfAvDoUmT2-WlwtqoqNX8_mChkjXZh2GweQtHe-3OQVHrck2xPRovtY21jFuaY_UpliCw4yOmkJjqonUBbOKqYzB0j5UR_6NuVx8Jh-9GQoev9Qjcvv9cjn72cyvf_yafZs3Vig-Nl70EvpJ1yqcomqVlcormDLRGc8M854LKz3rOUcnVG9a7Bx467veeIPeiSNyustd5_Rng2XUD2mTYz2p2VQIrtpWtlXFdiqbUykZvV7nUF_dagb6mbbe0daVtn6mrSfV8-UledM_ont1_MdbBXwnKHUVV5jfnH439QkjWova</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Razavi, S. Adeleh</creator><creator>Modarressi, Mohammad Hossein</creator><creator>Yaghmaei, Parichehr</creator><creator>Tavangar, S. Mohammad</creator><creator>Hedayati, Mehdi</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170901</creationdate><title>Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?</title><author>Razavi, S. Adeleh ; Modarressi, Mohammad Hossein ; Yaghmaei, Parichehr ; Tavangar, S. Mohammad ; Hedayati, Mehdi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-f3b50b4867e9e767c57f709138af1a1ff23c5f1b22ed37ba6e8d0fcf8bafaefd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinogenesis</topic><topic>Carcinoma, Papillary - blood</topic><topic>Carcinoma, Papillary - diagnosis</topic><topic>Carcinoma, Papillary - pathology</topic><topic>Case-Control Studies</topic><topic>Chromosome 10</topic><topic>Cowden syndrome</topic><topic>Diabetes</topic><topic>Diagnosis, Differential</topic><topic>Differential diagnosis</topic><topic>Down-Regulation</topic><topic>Endocrinology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Goiter</topic><topic>Goiter, Nodular - blood</topic><topic>Goiter, Nodular - diagnosis</topic><topic>Hereditary diseases</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Iran</topic><topic>Male</topic><topic>Malignancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Neoplasm Staging</topic><topic>Nodules</topic><topic>Normal Distribution</topic><topic>Original Article</topic><topic>Papillary thyroid carcinoma</topic><topic>Plasma levels</topic><topic>PTEN Phosphohydrolase - blood</topic><topic>PTEN protein</topic><topic>Science</topic><topic>Statistics, Nonparametric</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Thyroid Cancer, Papillary</topic><topic>Thyroid Gland - pathology</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - diagnosis</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Tumor Burden</topic><topic>Tumor suppressor genes</topic><topic>Tumor Suppressor Proteins - blood</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Razavi, S. Adeleh</creatorcontrib><creatorcontrib>Modarressi, Mohammad Hossein</creatorcontrib><creatorcontrib>Yaghmaei, Parichehr</creatorcontrib><creatorcontrib>Tavangar, S. Mohammad</creatorcontrib><creatorcontrib>Hedayati, Mehdi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Razavi, S. Adeleh</au><au>Modarressi, Mohammad Hossein</au><au>Yaghmaei, Parichehr</au><au>Tavangar, S. Mohammad</au><au>Hedayati, Mehdi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>57</volume><issue>3</issue><spage>428</spage><epage>435</epage><pages>428-435</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
PTEN
and
KLLN
are two tumor suppressor genes located in 10q23, share a bidirectional promoter and have roles in carcinogenesis. Formerly, the role of
PTEN
mutations and
KLLN
epimutations were identified in incidence of thyroid lesions in individuals with Cowden syndrome, a rare autosomal dominant inherited disorder. This study is the first of its type to assess PTEN and KLLN circulating levels in patients with sporadic papillary thyroid carcinoma (PTC) and compare to patients with multinodular goiter (MNG) and healthy individuals.
Methods
Plasma levels of PTEN and KLLN were determined by enzyme-linked immunosorbent assay in three groups consisted of PTC (
n
= 33), MNG (
n
= 26) and healthy persons (
n
= 30). The association of demographic/pathological characteristics with the levels of PTEN and KLLN were evaluated.
Results
A significant lower plasma levels of PTEN and KLLN were observed in PTC patients compared with those of healthy persons (PTEN, 9.43 ± 3.20 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.81 ± 0.83 vs. 2.57 ± 1.09 ng/ml,
P
= 0.005), while no statistical difference was found between PTC and MNG groups. Patients with MNG lesion had significantly lower levels of PTEN/KLLN (PTEN, 9.62 ± 2.97 vs. 16.96 ± 1.28 ng/ml,
P
= 0.000; KLLN, 1.34 ± 0.86 vs. 2.57 ± 1.09 ng/ml,
P
= 0.000) compared to the healthy controls. The demographic/pathological characteristics did not demonstrate an association with the levels of PTEN and KLLN.
Conclusions
The study suggests that the lowered levels of PTEN and KLLN are associated with both sporadic PTC and MNG tumorigenesis, but they cannot be considered as circulating biomarkers for differential diagnosis between malignancy and benignity in indeterminate thyroid nodules.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28755140</pmid><doi>10.1007/s12020-017-1368-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-008X |
| ispartof | Endocrine, 2017-09, Vol.57 (3), p.428-435 |
| issn | 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_journals_1933276656 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Biomarkers Biomarkers, Tumor - blood Carcinogenesis Carcinoma, Papillary - blood Carcinoma, Papillary - diagnosis Carcinoma, Papillary - pathology Case-Control Studies Chromosome 10 Cowden syndrome Diabetes Diagnosis, Differential Differential diagnosis Down-Regulation Endocrinology Enzyme-Linked Immunosorbent Assay Female Goiter Goiter, Nodular - blood Goiter, Nodular - diagnosis Hereditary diseases Humanities and Social Sciences Humans Internal Medicine Iran Male Malignancy Medicine Medicine & Public Health Middle Aged multidisciplinary Neoplasm Staging Nodules Normal Distribution Original Article Papillary thyroid carcinoma Plasma levels PTEN Phosphohydrolase - blood PTEN protein Science Statistics, Nonparametric Thyroid Thyroid cancer Thyroid Cancer, Papillary Thyroid Gland - pathology Thyroid Neoplasms - blood Thyroid Neoplasms - diagnosis Thyroid Neoplasms - pathology Tumor Burden Tumor suppressor genes Tumor Suppressor Proteins - blood Tumorigenesis |
| title | Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T13%3A50%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20levels%20of%20PTEN%20and%20KLLN%20in%20papillary%20thyroid%20carcinoma:%20can%20they%20be%20considered%20as%20novel%20diagnostic%20biomarkers?&rft.jtitle=Endocrine&rft.au=Razavi,%20S.%20Adeleh&rft.date=2017-09-01&rft.volume=57&rft.issue=3&rft.spage=428&rft.epage=435&rft.pages=428-435&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-017-1368-4&rft_dat=%3Cproquest_cross%3E1933276656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1933276656&rft_id=info:pmid/28755140&rfr_iscdi=true |